AbelZeta Pharma has announced the publication of clinical findings in Nature covering its armored autologous GPC3 CAR-T therapy for patients with advanced hepatocellular carcinoma. The update puts the company’s liver cancer program in the spotlight through a major scientific journal.
According to the announcement, the published work focuses on an autologous CAR-T approach targeting GPC3 in advanced hepatocellular carcinoma. AbelZeta describes itself as a global clinical-stage biopharmaceutical company developing innovative, proprietary cell-based therapies.
The publication is notable because it highlights clinical research tied to a solid tumor setting, an area where CAR-T therapies continue to draw significant interest. For AbelZeta, the Nature paper adds scientific visibility to its broader development efforts in oncology and cell therapy.
While the announcement emphasizes the journal publication and the therapy platform, it does not detail the full study findings in the available summary. Even so, the report marks an important milestone for AbelZeta’s GPC3 CAR-T program in advanced hepatocellular carcinoma.
